Xeris Biopharma Holdings (XERS) Net Equity Issued and Repurchased (2021 - 2022)
Xeris Biopharma Holdings' (XERS) quarterly Net Equity Issued and Repurchased came in at $30.0 million in Q1 2022, up 11.11% YoY from $27.0 million in Q1 2021, and up 11.11% on a QoQ basis from $27.0 million in Q1 2021.
Xeris Biopharma Holdings (XERS) Net Equity Issued and Repurchased (2021 - 2022) Analysis & Trends
Xeris Biopharma Holdings (XERS) has 2 years of Net Equity Issued and Repurchased data on file, last reported at $30.0 million in Q1 2022.
- Quarterly Net Equity Issued and Repurchased rose 11.11% year-over-year to $30.0 million in Q1 2022, while the trailing twelve-month figure through Dec 2022 was $30.0 million (up 11.11% YoY) and the FY2022 annual result came in at $30.0 million, up 11.11% from the prior year.
- Net Equity Issued and Repurchased climbed to $30.0 million in Q1 2022, from $27.0 million in the prior quarter.
- In the past five years, Net Equity Issued and Repurchased ranged from a high of $30.0 million in Q1 2022 to a low of $27.0 million in Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn | 700,000.00 |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn | 84.80 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - | - |
| 10 | Xeris Biopharma Holdings | 1.51 Bn | 1.39 Bn | 79.59 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | 30.00 Mn |
| Mar 31, 2022 | 30.00 Mn |
| Mar 31, 2021 | 27.00 Mn |
| Mar 31, 2021 | 27.00 Mn |